S&P 500   3,948.36 (+-0.01%)
DOW   32,119.88 (+0.05%)
QQQ   308.51 (-0.40%)
AAPL   158.57 (-0.23%)
MSFT   278.11 (+0.16%)
META   203.98 (-0.15%)
GOOGL   104.71 (-0.84%)
AMZN   97.41 (-1.32%)
TSLA   188.71 (-1.83%)
NVDA   264.95 (-2.56%)
NIO   8.94 (-3.56%)
BABA   85.69 (-0.96%)
AMD   97.37 (-2.90%)
T   18.50 (+0.22%)
F   11.42 (+0.00%)
MU   60.88 (-0.75%)
CGC   1.92 (+0.28%)
GE   91.76 (+0.19%)
DIS   93.47 (-2.46%)
AMC   4.46 (-0.22%)
PFE   40.15 (-0.07%)
PYPL   73.08 (+0.72%)
NFLX   327.07 (+2.09%)
S&P 500   3,948.36 (+-0.01%)
DOW   32,119.88 (+0.05%)
QQQ   308.51 (-0.40%)
AAPL   158.57 (-0.23%)
MSFT   278.11 (+0.16%)
META   203.98 (-0.15%)
GOOGL   104.71 (-0.84%)
AMZN   97.41 (-1.32%)
TSLA   188.71 (-1.83%)
NVDA   264.95 (-2.56%)
NIO   8.94 (-3.56%)
BABA   85.69 (-0.96%)
AMD   97.37 (-2.90%)
T   18.50 (+0.22%)
F   11.42 (+0.00%)
MU   60.88 (-0.75%)
CGC   1.92 (+0.28%)
GE   91.76 (+0.19%)
DIS   93.47 (-2.46%)
AMC   4.46 (-0.22%)
PFE   40.15 (-0.07%)
PYPL   73.08 (+0.72%)
NFLX   327.07 (+2.09%)
S&P 500   3,948.36 (+-0.01%)
DOW   32,119.88 (+0.05%)
QQQ   308.51 (-0.40%)
AAPL   158.57 (-0.23%)
MSFT   278.11 (+0.16%)
META   203.98 (-0.15%)
GOOGL   104.71 (-0.84%)
AMZN   97.41 (-1.32%)
TSLA   188.71 (-1.83%)
NVDA   264.95 (-2.56%)
NIO   8.94 (-3.56%)
BABA   85.69 (-0.96%)
AMD   97.37 (-2.90%)
T   18.50 (+0.22%)
F   11.42 (+0.00%)
MU   60.88 (-0.75%)
CGC   1.92 (+0.28%)
GE   91.76 (+0.19%)
DIS   93.47 (-2.46%)
AMC   4.46 (-0.22%)
PFE   40.15 (-0.07%)
PYPL   73.08 (+0.72%)
NFLX   327.07 (+2.09%)
S&P 500   3,948.36 (+-0.01%)
DOW   32,119.88 (+0.05%)
QQQ   308.51 (-0.40%)
AAPL   158.57 (-0.23%)
MSFT   278.11 (+0.16%)
META   203.98 (-0.15%)
GOOGL   104.71 (-0.84%)
AMZN   97.41 (-1.32%)
TSLA   188.71 (-1.83%)
NVDA   264.95 (-2.56%)
NIO   8.94 (-3.56%)
BABA   85.69 (-0.96%)
AMD   97.37 (-2.90%)
T   18.50 (+0.22%)
F   11.42 (+0.00%)
MU   60.88 (-0.75%)
CGC   1.92 (+0.28%)
GE   91.76 (+0.19%)
DIS   93.47 (-2.46%)
AMC   4.46 (-0.22%)
PFE   40.15 (-0.07%)
PYPL   73.08 (+0.72%)
NFLX   327.07 (+2.09%)

Sarepta Therapeutics - SRPT Stock Forecast, Price & News

$127.43
-0.95 (-0.74%)
(As of 03/24/2023 12:38 PM ET)
Add
Compare
Today's Range
$126.99
$130.38
50-Day Range
$117.84
$155.99
52-Week Range
$61.28
$159.84
Volume
346,292 shs
Average Volume
1.44 million shs
Market Capitalization
$11.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$165.88

Sarepta Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.92 Rating Score
Upside/​Downside
30.3% Upside
$166.41 Price Target
Short Interest
Bearish
9.18% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.65
Upright™ Environmental Score
News Sentiment
0.31mentions of Sarepta Therapeutics in the last 14 days
Based on 23 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.44) to $7.15 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

171st out of 989 stocks

Pharmaceutical Preparations Industry

69th out of 480 stocks


SRPT stock logo

About Sarepta Therapeutics (NASDAQ:SRPT) Stock

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Stock News Headlines

Why did Sarepta Therapeutics Stock Plummet?
SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
The Latest Analyst Ratings for Sarepta Therapeutics
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
SVB Securities Keeps Their Buy Rating on Sarepta Therapeutics (SRPT)
Sarepta Therapeutics (SRPT) Gets a Hold from Raymond James
See More Headlines
Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Company Calendar

Last Earnings
2/28/2023
Today
3/24/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRPT
Previous Symbol
NASDAQ:AVII
Employees
1,162
Year Founded
1980

Price Target and Rating

Average Stock Price Forecast
$166.41
High Stock Price Forecast
$206.00
Low Stock Price Forecast
$122.00
Forecasted Upside/Downside
+29.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
14 Analysts

Profitability

Net Income
$-703,490,000.00
Pretax Margin
-73.95%

Debt

Sales & Book Value

Annual Sales
$933.01 million
Book Value
$4.39 per share

Miscellaneous

Free Float
82,351,000
Market Cap
$11.29 billion
Optionable
Optionable
Beta
0.97

Social Links


Key Executives

  • Douglas S. IngramDouglas S. Ingram
    President, Chief Executive Officer & Director
  • Ian M. Estepan
    Executive VP, Chief Financial & Accounting Officer
  • Louise Rodino-KlapacLouise Rodino-Klapac
    Chief Scientific Officer & Executive VP
  • Bilal Arif
    Chief Technical Operations Officer
  • Dallan Murray
    Chief Customer Officer & Senior Vice President













SRPT Stock - Frequently Asked Questions

Should I buy or sell Sarepta Therapeutics stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 1 hold rating and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SRPT shares.
View SRPT analyst ratings
or view top-rated stocks.

What is Sarepta Therapeutics' stock price forecast for 2023?

14 equities research analysts have issued 1 year price objectives for Sarepta Therapeutics' shares. Their SRPT share price forecasts range from $122.00 to $206.00. On average, they expect the company's stock price to reach $166.41 in the next year. This suggests a possible upside of 29.6% from the stock's current price.
View analysts price targets for SRPT
or view top-rated stocks among Wall Street analysts.

How have SRPT shares performed in 2023?

Sarepta Therapeutics' stock was trading at $129.58 at the start of the year. Since then, SRPT shares have decreased by 0.9% and is now trading at $128.38.
View the best growth stocks for 2023 here
.

When is Sarepta Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our SRPT earnings forecast
.

How were Sarepta Therapeutics' earnings last quarter?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) released its quarterly earnings data on Tuesday, February, 28th. The biotechnology company reported ($1.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.28) by $0.04. The biotechnology company earned $258.43 million during the quarter, compared to the consensus estimate of $250.51 million. Sarepta Therapeutics had a negative trailing twelve-month return on equity of 117.29% and a negative net margin of 75.40%. Sarepta Therapeutics's quarterly revenue was up 28.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.42) earnings per share.

What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO?

15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sarepta Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV) and Walt Disney (DIS).

What is Sarepta Therapeutics' stock symbol?

Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."

Who are Sarepta Therapeutics' major shareholders?

Sarepta Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Sands Capital Management LLC (2.45%), Geode Capital Management LLC (1.39%), Avidity Partners Management LP (1.20%), Norges Bank (0.98%), Price T Rowe Associates Inc. MD (0.95%) and Assenagon Asset Management S.A. (0.83%). Insiders that own company stock include David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, Joseph Bratica, Louise Rodino-Klapac, M Kathleen Behrens, Michael Andrew Chambers, Richard Barry and Stephen Mayo.
View institutional ownership trends
.

How do I buy shares of Sarepta Therapeutics?

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sarepta Therapeutics' stock price today?

One share of SRPT stock can currently be purchased for approximately $128.38.

How much money does Sarepta Therapeutics make?

Sarepta Therapeutics (NASDAQ:SRPT) has a market capitalization of $11.29 billion and generates $933.01 million in revenue each year. The biotechnology company earns $-703,490,000.00 in net income (profit) each year or ($8.03) on an earnings per share basis.

How many employees does Sarepta Therapeutics have?

The company employs 1,162 workers across the globe.

Does Sarepta Therapeutics have any subsidiaries?
The following companies are subsidiares of Sarepta Therapeutics: Eisai, Myonexus Therapeutics, ST International Holdings Two Inc., Sarepta Securities Corp., and Sarepta Therapeutics Three LLC.
Read More
How can I contact Sarepta Therapeutics?

Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The official website for the company is www.sareptatherapeutics.com. The biotechnology company can be reached via phone at (617) 274-4000, via email at investors@sarepta.com, or via fax at 425-354-5038.

This page (NASDAQ:SRPT) was last updated on 3/24/2023 by MarketBeat.com Staff